• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

In Vivo . Epicardial Adipose Tissue as a Prognostic Marker in COVID-19

tetano

Editor, Senior Moderator
In Vivo


. 2024 Jan-Feb;38(1):281-285.
doi: 10.21873/invivo.13436. Epicardial Adipose Tissue as a Prognostic Marker in COVID-19

Hans-Jonas Meyer[SUP] #[/SUP][SUP] 1 [/SUP], Anar Aghayev[SUP] #[/SUP][SUP] 2 [/SUP], Mattes Hinnrichs[SUP] 2 [/SUP], Jan Borggrefe[SUP] 3 [/SUP], Alexey Surov[SUP] 3 [/SUP]



Affiliations
Abstract

Background/aim: Epicardial adipose tissue (EAT) has been established as a quantitative imaging biomarker associated with the prognosis of several diseases, especially cardiovascular diseases. The cardiac injury by coronavirus disease 2019 (COVID-19) might be linked to the EAT. This study aimed to use this prognostic marker derived from computed tomography (CT) images to predict 30-day mortality in patients with COVID-19.
Patients and methods: Consecutive patients with COVID-19 were retrospectively screened between 2020 and 2022. Overall, 237 patients (78 female, 32.9%) were included in the present study. The study end-point was the 30-day mortality. EAT was measured using the diagnostic CT in a semiquantitative manner. EAT volume and density were measured for each patient.
Results: Overall, 70 patients (29.5%) died within the 30-day observation period and 143 patients (60.3%) were admitted to the intensive care unit (ICU). The mean EAT volume was 140.9±89.1 cm[SUP]3[/SUP] in survivors and 132.9±77.7 cm[SUP]3[/SUP] in non-survivors, p=0.66. The mean EAT density was -71.9±8.1 Hounsfield units (HU) in survivors, and -67.3±8.4 HU in non-survivors, p=0.0001. EAT density was associated with 30-day mortality (p<0.0001) and ICU admission (p<0.0001). EAT volume was not associated with mortality and/or ICU admission.
Conclusion: EAT density was associated with 30-day mortality and ICU admission in patients with COVID-19.

Keywords: COVID-19; CT; Epicardial adipose tissue.

 
Back
Top Bottom